Actinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy

- Data from the Company’s Actimab-A program to be presented in the Clinical Experiences session being held on Wednesday, May 31, 2017

- Actinium is a sponsor of the conference being held May 30th - June 2nd, 2017 at Kanazawa University in Kanazawa, Japan

- Representatives from Actinium’s business development, clinical and executive teams to attend

NEW YORK, May 23, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that data from the Company’s Actimab-A program will be presented in an oral presentation at the 10th International Symposium on Targeted Alpha Therapy (TAT10) being held on May 30 – June 2, 2017 at Kanazawa University in Kanazawa, Japan. Actinium’s Actimab-A drug candidate is a targeted radioimmunotherapy that consists of the alpha emitting radioisotope actinium-225 linked to an anti-CD33 monoclonal antibody. Actimab-A is currently being studied in a 53-patient, open label, multicenter Phase 2 clinical trial in patients newly diagnosed with acute myeloid leukemia (AML) who are age 60 and above.

Dr. Mark Berger, Actinium’s Chief Medical Officer said, “I very much look forward to presenting data from our Actimab-A program at the symposium. Given its specific focus on alpha particle based therapies, I can think of no better venue to showcase Actimab-A. I am confident that symposium attendees will be excited to hear about Actimab-A’s potential in acute myeloid leukemia, where our studies have shown a promising safety and efficacy profile in this difficult to treat hematologic indication. The powerful alpha particles enable Actimab-A activity in an indication where traditional oncology agents have not been able to produce effective results.”

Additional information about TAT-10 can be found via the symposium’s link: http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/

Details on Actinium’s oral presentation are below:

**Date:** Wednesday, May 31, 2017  
**Session:** Clinical Experiences
Title: Efficacy of $^{225}$Ac-labeled anti-CD33 antibody in acute myeloid leukemia (AML) correlates with peripheral blast count

Actinium’s Executive Chairman Sandesh Seth said, “Actinium is excited to once again be a sponsor of the International Symposium on Targeted Alpha Therapy. This conference has become the leading scientific forum and a key event in the field of alpha particle based targeted therapies. The symposium brings together thought leaders in the field from the pharmaceutical industry, government agencies and academic based researchers who continue to advance the field and establish alpha radiation as an effective therapeutic modality. As evidenced by the quality of the scientific, technological and clinical abstracts, this year’s symposium is an excellent showcase for the promise that alpha based therapies hold based on their differentiated biological profile compared to other forms of radiation and our team is looking forward to presenting Actimab-A and meeting with symposium attendees.”

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) product candidate, is currently in a 53-patient, multicenter Phase 2 trial for patients newly diagnosed with AML age 60 and above. Actimab-A is being developed as a first-line therapy and is a monotherapy that is administered via two 15-minute injections that are given 7 days apart. Actimab-A targets CD33, a protein abundantly expressed on the surface of AML cells via the monoclonal antibody, HuM195, which carries the potent cytotoxic radioisotope actinium-225 to the AML cancer cells. Actinium-225 gives off high-energy alpha particles as it decays, which kill cancer cells and as actinium-225 decays it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Actimab-A is a second-generation therapy from the Company's HuM195-Alpha program, which was developed at Memorial Sloan Kettering Cancer Center and has now been studied in over 90 patients in four clinical trials. Actimab-A has been granted Orphan Drug Designation for newly diagnosed AML in patients 60 and above by the U.S. Food and Drug Administration and the European Medicines Agency.

About Actinium's Alpha Particle Immunotherapy Platform

Actinium’s Alpha Particle Immunotherapy (APIT) platform is a highly potent and selective form of targeted payload radioimmunotherapy. The APIT platform is based on attaching the powerful alpha emitting radioisotope Actinium-225 to monoclonal antibodies (mAbs), which are large molecules capable of binding specifically to cancer cells. By virtue of carrying alpha emitters, mAbs bring Actinium-225 directly to cancer cells where alpha emitters can selectively kill the targeted cell. Actinium-225 emits significant energy making it a potent against targeted cancer cells but this energy only travels extremely short distances limiting damage to healthy tissues. Due to the targeting of this energy by way of the mAbs bringing the alpha emitting isotopes directly to cancer cells, Actinium believes Actinium-225 enabled therapies will result in potentially more effective and at the same time tolerable therapies.

About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more about Actinium Pharmaceuticals, please visit www.actiniumpharma.com and to follow @ActiniumPharma on Twitter please visit, www.twitter.com/actiniumpharma.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.

Steve O'Loughlin
Vice President, Finance and Corporate Development
soloughlin@actiniumpharma.com